Menu
Your Cart

Apostle Triton Bioinformatics Technology

Apostle Triton is a bioinformatics technology that utilizes the data from a curated internal cancer database of 30,000 patients with an unprecedented resolution.

Background

  • Cancer is a genetically heterogeneous disease.
  • Somatic mutations exist in both cancer and normal cells.
  • We still know very little about the genetics of cancer. There is a lacking of a comprehensive and coherent way to mine the big data repository of cancer genetics and apply the applicable findings.
  • The clinical application of liquid biopsy is further complicated by the characteristics of cell free tumor nucleic acids: low concentration, complex fragmentation, etc.

Here, we introduce Apostle Triton, a bioinformatics framework designed for liquid biopsy, which utilizes the big data from cancer genomics, evaluates disease effects of somatic mutations/variants and expression signatures, and apply the findings in the settings of liquid biopsy.

Apostle Triton Website
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.